Video Experimental Relacionado

Updated: May 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Determinantes genéticos de los niveles plasmáticos de dabigatrán y su relación con el sangrado

Guillaume Paré¹, Niclas Eriksson, Thorsten Lehr

¹Population Health Research Institute, Hamilton Health Sciences and McMaster University, David Braley Cardiac Vascular and Stroke Research Institute, 237 Barton St E, Room C3-103, Hamilton, ON, Canada L8L 2X2. pareg@McMaster.ca

|March 8, 2013

Resumen

Las variantes genéticas influyen en las concentraciones de dabigatrán y el riesgo de sangrado. El polimorfismo CES1 rs2244613 está relacionado con una menor exposición al fármaco y una reducción de los eventos de sangrado en pacientes con fibrilación auricular.

Área de la Ciencia:

La farmacogenómica es la farmacogenómica.
Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
Genética La genética.

Sus antecedentes:

Dabigatran etexilato ofrece una prevención eficaz del accidente cerebrovascular en la fibrilación auricular con un buen perfil de seguridad en comparación con la warfarina.
La variabilidad interindividual en las concentraciones de dabigatrán sugiere un papel para los factores genéticos.
Investigar las influencias genéticas puede optimizar el tratamiento con dabigatrán y los resultados de los pacientes.

Objetivo del estudio:

Para identificar las variantes genéticas asociadas con las concentraciones de dabigatrán y los resultados clínicos.
Explorar el impacto de las variaciones genéticas en la seguridad y eficacia del dabigatrán.
Comprender las diferencias interindividuales en la respuesta al tratamiento con dabigatrán.

Principales métodos:

Estudio de asociación de todo el genoma (GWAS) realizado en 2944 participantes del ensayo de evaluación aleatoria de la terapia anticoagulante a largo plazo (RE-LY).
Análisis de polimorfismos de un solo nucleótido (SNP) que incluyen el CES1 rs2244613, el ABCB1 rs4148738, y el CES1 rs8192935.
Evaluación estadística de las asociaciones entre las variantes genéticas, las concentraciones mínimas y máximas de dabigatrán y los eventos hemorrágicos / isquémicos.

Principales resultados:

El CES1 SNP rs2244613 se asoció significativamente con menores concentraciones bajas de dabigatrán y un menor riesgo de cualquier sangrado.
El transporte del alelo menor CES1 rs2244613 (32,8% de los pacientes) se correlacionó con una disminución del 15% en las concentraciones mínimas por alelo.
Los portadores del alelo menor CES1 rs2244613 experimentaron significativamente menos sangrado con dabigatrán en comparación con la warfarina.
No se encontró una asociación significativa entre las variantes genéticas estudiadas y los eventos isquémicos.

Conclusiones:

El polimorfismo CES1 rs2244613 es un determinante clave de la exposición al dabigatrán y el riesgo de sangrado.
El perfil genético, específicamente para CES1 rs2244613, puede ayudar a personalizar la terapia con dabigatrán.
Los hallazgos apoyan el papel de la farmacogenómica en la optimización de las estrategias de tratamiento con anticoagulantes.

Más Videos Relacionados

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Videos de Conceptos Relacionados

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...